In addition, Chen et al reported more frequent upregulation of PD‐L1 on tumor cells in EBV+ DLBCL and EBV+ post‐transplant LPDs (100% and 60% of cases, respectively).17 One potential explanation for the discrepancy with our data is the use of different antibodies. The gene discussed is CD274; the disease is neoplasm.